Full profile
| Also known as | L-alpha-glycerylphosphorylcholine, Choline alphoscerate, α-GPC |
|---|---|
| Best for | Choline delivery where a rationale exists · A comparison point against citicoline · Mostly studied in aging/impaired cognition, not healthy adults |
| Evidence grade | Grade C · Limited: early or small human trials |
| Studied dose range | 300–600 mg/day in studies; dose-conscious given the safety discussion. |
| Time to effect | Some acute choline-availability effects; cognition studies run over weeks. |
| Best form | Alpha-GPC (often a moisture-controlled branded form). For a healthy-adult cognition product, citicoline is the more defensible choline source. |
| Food sources | Supplemental form; dietary choline: eggs, liver, soybeans, meat |
Evidence, honestly graded
Most positive cognition trials are in dementia or post-stroke recovery populations, with sparse healthy-adult data. The key honest caveat is Lee et al. 2021 (JAMA Network Open), a South Korean cohort of roughly 12 million adults aged 50 and older, which found alpha-GPC use associated with a dose-responsive ~43% higher 10-year stroke risk (adjusted HR ≈1.43), an association that persisted in a 4-year lag analysis meant to rule out reverse causation. A 2025 Korean cohort study did not fully replicate the association; both studies are observational, so this is a safety signal, not proven causation, but it's large and holds the grade down regardless of the efficacy data. Citicoline has cleaner healthy-adult attention data and no comparable signal.
See the full grading rubric (study type, replication, population match, and dose adequacy) in The Evidence Standard.
365 natural health products with an active licence in Health Canada's LNHPD list Alpha-GPC as a medicinal ingredient.
That makes Alpha-GPC a recognized, licensable medicinal ingredient in Canada, regulated by Health Canada's Natural and Non-prescription Health Products Directorate, which issues each licensed natural health product a Natural Product Number (NPN). Search the LNHPD to verify.
Side effects
- Headache
- Heartburn or GI upset
- Dizziness
- Insomnia at higher doses
The full side-effect breakdown: Alpha-GPC Side Effects: What to Watch For (and the Stroke-Risk Signal).
Who should avoid it or check first
- Personal or strong family history of stroke or high cardiovascular risk (given the observational signal), without clinician review
- Pregnant or breastfeeding without clinician guidance
Interactions
- Theoretically additive with cholinergic drugs (e.g. cholinesterase inhibitors); clinician review
- Consider cardiovascular context for higher-risk individuals
Stacks well with
Use caution stacking with
- Citicoline (redundant; do not stack two high-dose choline sources without rationale)
- Other high-dose choline donors
What to look for on a label
- State the choline delivered and avoid disease/treatment framing. Alpha-GPC's better-studied populations are impaired, not healthy adults.
- Choline sources map to Health Canada's Cognitive Function Products monograph pathway, but the observational stroke association means a conservative brand should favour citicoline or carry a cautious, non-overreaching claim; do not present alpha-GPC as cardiovascular-safe-confirmed.
References
- Lee 2021, JAMA Network Open: alpha-GPC and 10-year stroke risk. South Korean cohort of ~12 million adults 50+; alpha-GPC use associated with a dose-responsive ~43% higher 10-year stroke risk (adjusted HR ≈1.43), persisting after a 4-year lag analysis. Association, not proven causation. PMID 34817582; doi:10.1001/jamanetworkopen.2021.36008. Educational.
- 2025 Korean cohort study: partial non-replication. A subsequent Korean cohort analysis did not fully replicate the Lee 2021 stroke association. Both studies are observational; noted here so the safety discussion isn't one-sided. Educational, not a product claim.
- Health Canada NNHPD Cognitive Function Products monograph. Choline-type cognition-claim pathway; confirm alpha-GPC eligibility and claim wording against live monograph text. webprod.hc-sc.gc.ca/nhpid-bdipsn.
Entries above without a linked identifier are either editorial summaries of a wider body of literature or references to a named authority (a regulator or government monograph) cited by name rather than by a single paper.
Grades and studied doses are our conservative reading of the human research, shown for education. They are not product claims, and a studied dose is not a recommended dose.
Revision history
Every change to this ingredient's evidence status, dated and explained. The full cross-library log lives at Evidence Updates.
- 2026-07-07New profile
Initial profile published at Grade C: most positive cognition trials are in dementia or post-stroke populations with sparse healthy-adult data; the profile carries a stroke-risk association caveat.
See how Alpha-GPC compares on grade, dose, and goal in the Evidence Explorer.
